SEC and FDA Announce Three-Year Cooperation Agreement
The SEC and FDA have entered a three-year Memorandum of Understanding to share information and coordinate oversight of financial markets and FDA-regulated products.
- The SEC and FDA entered into a Memorandum of Understanding.
- The MOU establishes information-sharing protocols between the agencies.
- It is designed to improve market oversight and compliance.
- The MOU remains in effect for three years.
- It may be extended or modified by mutual written consent.
The Securities and Exchange Commission and the Food and Drug Administration now operate under a formal framework for sharing information and coordinating regulatory and enforcement work.
The two agencies announced a Memorandum of Understanding designed to improve market oversight and compliance, including protocols for exchanging information relevant to both missions.
The agreement is intended to help the agencies carry out their missions of ensuring financial-market integrity and protecting public health.
SEC Chairman Paul S. Atkins said FDA-related disclosures by public companies have a significant impact on markets and called the FDA a valuable partner in administering and enforcing disclosure requirements under federal securities laws.
The MOU remains in effect for three years and may be extended or modified by mutual written consent.
Corrections: [email protected]